KFAS
OCUL icon

Keating Financial Advisory Services’s Ocular Therapeutix OCUL Stock Holding History

Keating Financial Advisory Services’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59 Hold
6
– – ﹤0.01% 2503
2026
Q1 		$51 Sell
6
-5
-45% -$48 ﹤0.01% 2451
2025
Q4 		$134 Buy
+11
New +$134 ﹤0.01% 2111

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Keating Financial Advisory Services's OCUL Position: Q2 2026 in Review

Keating Financial Advisory Services held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 6 shares worth $59. The position accounts for ﹤0.01% of the portfolio, ranked #2503.

Keating Financial Advisory Services first reported a position in OCUL in Q4 2025 and has held it in 3 quarters since. The position peaked at $134 in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Keating Financial Advisory Services held 6 shares of Ocular Therapeutix worth $59 as of Q2 2026.
  • Keating Financial Advisory Services left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2503 holding.
  • Keating Financial Advisory Services first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Ocular Therapeutix position peaked at $134 in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.